Ovarian Cancer Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
S
Not yet recruiting
  • Ovarian Cancer
  • +2 more
  • Primary debulking surgery
  • +2 more
  • Shanghai, China
    Zhongshan Hospital, Fudan University
2022-01-17
Jan 17, 2022
K
Not yet recruiting
  • Ovarian Cancer
  • +3 more
  • (no location specified)
2022-01-06
Jan 6, 2022
Z
Recruiting
  • Gynecologic Cancer
  • +11 more
  • Neoantigen specific TCR-T cell drug product
  • Houston, Texas
    MD Anderson Cancer Center
2022-01-15
Jan 15, 2022
N
Not yet recruiting
  • Peritoneal Carcinomatosis
  • +7 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-01-18
Jan 18, 2022
A
Recruiting
  • Ovarian Cancer
  • +3 more
    • Busan, Korea, Republic of
    • +8 more
    2022-01-13
    Jan 13, 2022
    P
    Recruiting
    • Non-small Cell Lung Cancer
    • +9 more
    • Little Rock, Arkansas
    • +72 more
    2022-01-12
    Jan 12, 2022
    N
    Completed
    • Ovarian Cancer
    • +4 more
      • New York, New York
        Columbia University
      2022-01-13
      Jan 13, 2022
      M
      Recruiting
      • Ovarian Cancer
      • +2 more
      • Pembrolizumab
      • +4 more
      • Monterey, California
      • +13 more
      2022-01-12
      Jan 12, 2022
      E
      Recruiting
      • Ovarian Cancer
      • +68 more
      • Phoenix, Arizona
      • +5 more
      2022-01-10
      Jan 10, 2022
      N
      Active, not recruiting
      • Melanoma
      • +4 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center, 9000 Rockville Pi
        2022-01-11
        Jan 11, 2022
        O
        Recruiting
        • Non Small Cell Lung Cancer
        • +16 more
        • Scottsdale, Arizona
        • +30 more
        2021-12-30
        Dec 30, 2021
        H
        Recruiting
        • Ovarian Cancer
        • Sentinel Lymph Node
        • Sentinel node detection
        • Barcelona, Spain
          Núria Agustí Garcia
        2022-01-05
        Jan 5, 2022
        A
        Not yet recruiting
        • Ovarian Cancer
        • Angers, France
        • +36 more
        2022-01-05
        Jan 5, 2022
        F
        Completed
        • Breast Cancer
        • +3 more
        • FPA150
        • Pembrolizumab
        • Scottsdale, Arizona
        • +17 more
        2022-01-06
        Jan 6, 2022
        H
        Not yet recruiting
        • Ovarian Cancer
        • Carboplatin AUC 5 and paclitaxel
        • Bintrafusp alfa (M7824)
        • Pittsburgh, Pennsylvania
          University of Pittsburgh Medical Center
        2022-01-06
        Jan 6, 2022
        U
        Not yet recruiting
        • Ovarian Cancer
          • (no location specified)
          2022-01-10
          Jan 10, 2022
          A
          Enrolling by invitation
          • Ovarian Cancer
          • Breast Cancer
          • Shreveport, Louisiana
          • +95 more
          2022-01-09
          Jan 9, 2022
          N
          Enrolling by invitation
          • Breast Cancer
          • +2 more
            • Bethesda, Maryland
              National Institutes of Health Clinical Center
            2022-01-08
            Jan 8, 2022
            V
            Recruiting
            • Ovarian Cancer
            • Scottsdale, Arizona
            • +35 more
            2022-01-05
            Jan 5, 2022
            P
            Active, not recruiting
            • Advanced Solid Tumors
            • +7 more
            • TALZENNA capsule
            • Talazoparib soft gel capsule
            • Downey, California
            • +42 more
            2022-01-05
            Jan 5, 2022
            G
            Recruiting
            • Breast Cancer
            • +7 more
            • GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive cells.
            • Copenhagen, Denmark
              Rigshospitalet (Copenhagen University Hospital)
            2021-12-17
            Dec 17, 2021